Literature DB >> 12057088

Local complications of non-small-cell lung cancer.

Joshua R Sonett1.   

Abstract

Because of the stage-specific treatment of lung cancer, significant strides have been made in the treatment strategies for patients with non-small-cell carcinoma. Unfortunately, despite aggressive therapy, most patients will die within 5 years of diagnosis. Although the predominant cause of death will be secondary to the systemic nature of the cancer, most patients also will suffer significant decrements in their quality of life and functional status secondary to local complications. Addressing and treating the local complications of lung cancer aggressively may directly and immediately improve the quality of life and functional status of patients with extensive lung cancer. Improvements in the treatment of local complications of lung cancer that lead to improved performance status also may have an impact on the long-term survival of these patients.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12057088     DOI: 10.1007/s11864-002-0042-z

Source DB:  PubMed          Journal:  Curr Treat Options Oncol        ISSN: 1534-6277


  25 in total

1.  High-dose-rate endobronchial brachytherapy effectively palliates symptoms due to airway tumors: the 10-year M. D. Anderson cancer center experience.

Authors:  J F Kelly; M E Delclos; R C Morice; A Huaringa; P K Allen; R Komaki
Journal:  Int J Radiat Oncol Biol Phys       Date:  2000-10-01       Impact factor: 7.038

2.  Thoracic reirradiation for symptomatic relief after prior radiotherapeutic management for lung cancer.

Authors:  E L Gressen; M Werner-Wasik; J Cohn; A Topham; W J Curran
Journal:  Am J Clin Oncol       Date:  2000-04       Impact factor: 2.339

Review 3.  Photodynamic therapy in lung cancer.

Authors:  D Ost
Journal:  Oncology (Williston Park)       Date:  2000-03       Impact factor: 2.990

4.  Long-term observations of the patterns of failure in patients with unresectable non-oat cell carcinoma of the lung treated with definitive radiotherapy. Report by the Radiation Therapy Oncology Group.

Authors:  C A Perez; T F Pajak; P Rubin; J R Simpson; M Mohiuddin; L W Brady; R Perez-Tamayo; M Rotman
Journal:  Cancer       Date:  1987-06-01       Impact factor: 6.860

5.  Endoscopic relief of malignant airway obstruction.

Authors:  D J Mathisen; H C Grillo
Journal:  Ann Thorac Surg       Date:  1989-10       Impact factor: 4.330

6.  Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.

Authors:  K Furuse; M Fukuoka; M Kawahara; H Nishikawa; Y Takada; S Kudoh; N Katagami; Y Ariyoshi
Journal:  J Clin Oncol       Date:  1999-09       Impact factor: 44.544

7.  Quality of life in patients with lung cancer: a review of literature from 1970 to 1995.

Authors:  A Montazeri; C R Gillis; J McEwen
Journal:  Chest       Date:  1998-02       Impact factor: 9.410

8.  Recursive partitioning analysis of 1999 Radiation Therapy Oncology Group (RTOG) patients with locally-advanced non-small-cell lung cancer (LA-NSCLC): identification of five groups with different survival.

Authors:  M Werner-Wasik; C Scott; J D Cox; W T Sause; R W Byhardt; S Asbell; A Russell; R Komaki; J S Lee
Journal:  Int J Radiat Oncol Biol Phys       Date:  2000-12-01       Impact factor: 7.038

Review 9.  Chemical pleurodesis for malignant pleural effusions.

Authors:  P B Walker-Renard; L M Vaughan; S A Sahn
Journal:  Ann Intern Med       Date:  1994-01-01       Impact factor: 25.391

10.  Endobronchial management of benign, malignant, and lung transplantation airway stenoses.

Authors:  J R Sonett; R J Keenan; P F Ferson; B P Griffith; R J Landreneau
Journal:  Ann Thorac Surg       Date:  1995-06       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.